Mark your calendars: Aviv Regev to give Omenn lecture March 25

The ninth annual Gilbert S. Omenn Lecture is approaching, with this year’s talk presented by Aviv Regev, PhD.

This lecture series invites high-profile scientists to give talks on research in bioinformatics, data science and the field at large.

This year’s lecture, titled “From Cell Atlases to Medicines, with AI,” will be presented by Aviv Regev, PhD. Dr. Regev, is the Executive Vice President, Genentech Research and Early Development– a biotech company which aims to discover and develop medicines – as the head and executive vice president of Research and Early Development.

Regev’s research has made her a leader in deciphering molecular circuits that govern cells, tissues and organs in health, and their malfunction in disease. Her work pioneered foundational experimental and computational methods in single-cell genomics, enabling greater understanding of cell and tissue functions.

Following the lecture will be a poster session in the Omenn Atrium, featuring research posters from the host departments and programs. The host departments include: the Gilbert S. Omenn Department of Computational Medicine & Bioinformatics (DCMB), Center for Computational Medicine & Bioinformatics (CCMB), and Genome Science Training Program, Life Sciences Institute, and Single Cell Spatial Analysis Program.

The Omenn Lecture is a time to hear the latest from international leaders in Computational Medicine and Bioinformatics. This year’s talk will be no exception. Dr. Aviv Regev is an international leader in Early-Stage Drug Research and Development for Genentech and with Roche. She is a visionary pharmaceutical executive, research leader and an expert on teaching and mentorship.

Brian Athey, PhD 
Founding Chair, DCMB

The Omenn Lecture is named in honor of Gilbert S. Omenn, who is the Harold T. Shapiro Distinguished University Professor DCMB, Internal Medicine, Human Genetics and Public Health. Omenn is also the director of CCMB.

Omenn’s career has it all: research, public service and philanthropy. His current research focuses on proteogenomics of alternative splicing in cancers. His research legacy was honored by AAAS this year, as the recipient of the prestigious Philip Hauge Abelson Prize.